BioNTech

BioNTech operates a diversified mRNA pipeline including oncology candidates using lipid nanoparticles. It shares mRNA roots with Kernal but emphasizes personalized neoantigen vaccines over in vivo CAR-T selectivity. Larger scale and approved products give it commercial reach Kernal currently lacks.